Keyword
in
Collection
Date
to
Houston Voice, No. 1018, April 28, 2000
File 004
Citation
MLA
APA
Chicago/Turabian
Houston Voice, No. 1018, April 28, 2000 - File 004. 2000-04-28. University of Houston Libraries. University of Houston Digital Library. Web. October 18, 2019. https://digital.lib.uh.edu/collection/montrose/item/1889/show/1863.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

(2000-04-28). Houston Voice, No. 1018, April 28, 2000 - File 004. Montrose Voice. University of Houston Libraries. Retrieved from https://digital.lib.uh.edu/collection/montrose/item/1889/show/1863

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

Houston Voice, No. 1018, April 28, 2000 - File 004, 2000-04-28, Montrose Voice, University of Houston Libraries, accessed October 18, 2019, https://digital.lib.uh.edu/collection/montrose/item/1889/show/1863.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

URL
Embed Image
Compound Item Description
Title Houston Voice, No. 1018, April 28, 2000
Contributor
  • Hennie, Matthew A.
Publisher Window Media
Date April 28, 2000
Language English
Subject
  • LGBTQ community
  • LGBTQ people
  • Gay liberation movement
Place
  • Houston, Texas
Genre
  • newspapers
Type
  • Text
Identifier OCLC: 31485329
Collection
  • University of Houston Libraries Special Collections
  • LGBT Research Collection
  • Montrose Voice
Rights In Copyright
Note This item was digitized from materials loaned by the Gulf Coast Archive and Museum (GCAM).
Item Description
Title File 004
Transcript HOUSTON VOICE • APRIL 28, 2000 (Holm m HIGHLY EFFECTIVE THERAPY CRIXfVAN in combination wrth antiretroviral agents is a powerful protease inhibitor that fights HfV and is among the preferred treatments for HIV in federal healthcare guidelines. CRfX/VAN can help reduce the chance of'inesses and death associated with HIV; CRIX/VAN can also he(p lower the anxxit c/HIV hyour body (caSed "viral load") and raise your CD4 T-cefl count, as shown in studies -over a one-year penbd. Some patients may not experience these effects. CRIXIVAN is not a cure for HIV or AIDS. m DURABLE RESULTS In a landmark study, over 90% of 31 patients receiving a combination of CRIXIVAN, AZT and 3TC reduced their serum viral load below the limit of detection after 24 weeks. Importantly the limited number of patients who chose to stay with the study for longer periods of time maintained these results through the one-year mark. In a separate study, 30% of 261 patients receiving dual therapy of CRIXIVAN and AZT had serum viral loads below the limit of detection at 48 weeks. In another landmark study, 43% of 40 patients receiving combination therapy with CRIXfVAN, AZT and 3TC had plasma viral loads below the limit of detection at 40 weeks. In this study of over 1,000 patients, the group of patients receiving CRIX/VAN along with 37C and AZT achieved a reduction in deaths and AIDS-defining illnesses over those taking 3TC and AZT alone. Overall, the number of deaths was inadequate to assess the impact of CRIXIVAN on survival. Blood viraJ loads were measured by available tests and the virus may still be present in other organ systems. ■ THINGS YOU SHOULD KNOW ABOUT CRIXIVAN CRIXIVAN can be taken with a light meal or on an empty stomach. Some patients treated with CRJXTvAN may develop kidney stones. For some, this can lead to more severe kidney problems, including kidney failure. Drinking at least 6 glasses of water each day may help reduce the chance of forming a kidney stone. Other side effects reported include rapid breakdown of red blood cells and liver problems. As with other protease inhibitors, changes in body fat, increased bleeding in some patients wrth hemophilia, and increased blood sugar levels or diabetes have been reported. Additionally, severe muscle pain and weakness have occurred in patients also taking cholesterol-lowering/nedicines called "statins!' There are some common medications and AIDS-related medications you should not take with CRIXIVAN. Discuss all medications you are taking or plan to take with your doctor For more detailed information about CRIXIVAN, please read the information immediately following this advertisement. Guidelines for the Use of Anbrertroviral Agents in HIV-infected Adults and Adolescents. Fane) on Clinical Practices for Treatment of HIV Infection, Department of Health and Human Services (DHHS). May 5,1999. Remember to ask your doctor about CRIXIVAN. CRIXIVAN'
File Name uhlib_31485329_n1018_003.jpg